Archer Daniels Midland Company (ADM) and Qingdao Vland Biotech Group Co Ltd have entered into a joint development agreement for the development and commercialization of enzymes for animal feed applications.
In addition to ADM’s research centre in Decatur, Illinois, ADM will open a new US enzyme research and development lab in California that will directly support activities being undertaken in the joint development agreement. Vland will also conduct research and development in its Qingdao research laboratory, which will be upgraded to a new state-of-the-art facility.
Under the agreement, the companies will share enzyme-producing strains as a basis for the development of feed enzymes that will improve animal nutrition and health. Products developed under the agreement will be commercialized by both companies.
“This agreement and the opening of our new enzyme lab will significantly enhance our ability to develop products for the fast-growing enzyme market. The agreement will give our research and development team access to new enzyme strains, and the new US-based enzyme research lab will provide us with the resources to use those strains to develop new, state-of-the-art feed enzymes. We’re looking forward to adding these capabilities to our already strong array of animal nutrition products and solutions,” said Todd Werpy, chief technology officer, ADM.
Archer Daniels Midland Company (ADM) and Qingdao Vland Biotech Group Co Ltd have entered into a joint development agreement for the development and commercialization of enzymes for animal feed applications.
In addition to ADM’s research centre in Decatur, Illinois, ADM will open a new US enzyme research and development lab in California that will directly support activities being undertaken in the joint development agreement. Vland will also conduct research and development in its Qingdao research laboratory, which will be upgraded to a new state-of-the-art facility.
Under the agreement, the companies will share enzyme-producing strains as a basis for the development of feed enzymes that will improve animal nutrition and health. Products developed under the agreement will be commercialized by both companies.
“This agreement and the opening of our new enzyme lab will significantly enhance our ability to develop products for the fast-growing enzyme market. The agreement will give our research and development team access to new enzyme strains, and the new US-based enzyme research lab will provide us with the resources to use those strains to develop new, state-of-the-art feed enzymes. We’re looking forward to adding these capabilities to our already strong array of animal nutrition products and solutions,” said Todd Werpy, chief technology officer, ADM.
No comments:
Post a Comment